The Human Immune Monitoring Center at Mount Sinai is an internationally recognized resource. Our primary objective is to comprehensively map human immune responses across a wide range of disease settings, employing leading-edge platforms and upholding the highest standards of immunoassays. We excel in the development of customized experimental strategies to explore and understand the intricate mechanisms of the immune system and in using this knowledge to efficiently combat both existing and emerging diseases. We have forged partnerships with numerous academic institutions and industry sectors at regional, national, and international levels, facilitating collaboration and knowledge exchange. We are committed to maintaining a delicate balance between driving forward innovation and optimizing standardization. Our rigorous quality control enables us to contribute robust and reliable findings to the field of immune monitoring.

The Center takes pride in our dedicated team of 25 scientists, including eight investigators with a PhD degree and nine with master’s degrees. The expertise of our investigators extends beyond immune-oncology and encompasses a broad array of diseases such as autoimmunity, allergy, and neuro-immunology. We apply the principles of immune monitoring and biomarker development strategies to tackle the diverse medical challenges faced by our communities.

During the COVID-19 pandemic, we contributed to global efforts aimed at containing the virus. The Center processed thousands of biospecimens from COVID-19 patients exhibiting a wide range of symptoms. Our effort shed light on disease mechanisms associated with pathological inflammation, cancer comorbidities, as well as sequelae of long COVID.

Notably, we were identified by the National Cancer Institute as one of four sites in the country with extensive expertise in high-dimensional assays to identify biomarkers associated with response or resistance to immunotherapy, which is one of the major goals of the Cancer Moonshot Program. Consequently, the Center was established as a founding member of the Cancer Immune Monitoring and Analysis Center, an initiative led by the National Institutes of Health (NIH).  

The Center has led more than 400 clinical trials and provided support for more than 1,000 research projects. We currently have 35 currently active federal grants, amounting to $41 million in NIH funding. Our contributions have been instrumental in studies published in journals such as Nature, Science, Nature Medicine, Cell, and The New England Journal of Medicine.